TKI/Immunotherapy Combos in Endometrial Cancer

Christian Marth, MD, PhD, discusses implications of the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer and other research efforts of interest.

EP. 1: Prognosis and Survival Outcomes for Advanced/Recurrent Endometrial Cancer

April 3rd 2024

Christian Marth, MD, PhD, highlights the prognosis and survival outcomes for patients who are diagnosed with advanced or recurrent endometrial cancer.

EP. 2: Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer

April 3rd 2024

Christian Marth, MD, PhD, discusses the differences between mismatch repair–deficient and –proficient subtypes of advanced/recurrent endometrial cancer and other research efforts of interest.

EP. 3: Exploring Unmet Needs for the LEAP-001 Trial in Advanced Endometrial Cancer

April 8th 2024

Christian Marth, MD, PhD, discusses the unmet needs that led to the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer and other research efforts of interest.

EP. 4: Efficacy and Safety Data With Pembrolizumab/Lenvatinib in LEAP-001 of Endometrial Cancer

April 8th 2024

Christian Marth, MD, PhD, discusses efficacy and safety findings from the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer.

EP. 5: Next Steps With Pembrolizumab/Lenvatinib in Endometrial Cancer

April 15th 2024

Christian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm.